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ease burden associated with NBCCS diagnosed in Swiss pa-
tients is significant and comparable to that of other coun-
tries. Regular skin examination and oromaxillary examina-
tions should be performed early in diagnosis, and patients 
should undergo early UV protection. Nodular BCC is the 
most common BCC subtype in this patient population. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 The nevoid basal cell carcinoma syndrome (NBCCS) 
was first described by Gorlin and Goltz in their article 
‘Multiple nevoid basal-cell epithelioma, jaw cysts and bi-
fid rib. A syndrome’, published in the  New England Jour-
nal of Medicine in 1960  [1] . The NBCCS – also referred 
to as Gorlin-Goltz syndrome – describes an autosomal 
dominant disease characterized by a variety of develop-
mental disorders and neoplasias, especially basal cell car-
cinomas (BCCs) at younger ages. The prevalence is esti-
mated from 1: 31,000  [2] up to 1: 256,000  [3] . Based on 
these prevalence rates, the NBCCS population in Switzer-
land would be estimated to be 32–266 based on a popula-
tion of 8,237,700 inhabitants  [4] . NBCCS is most com-
monly caused by a genetic mutation in the gene  PTCH1  – 
 Key Words 
 Gorlin-Goltz syndrome · Nevoid basal cell carcinoma 
syndrome · Basal cell carcinoma · Jaw cysts 
 Abstract 
 Background: Nevoid basal cell carcinoma syndrome (NBCCS, 
Gorlin-Goltz syndrome) presents various symptoms and can 
disfigure patients. The estimated prevalence is around 
1: 100,000.  Objective: To systematically investigate the clini-
cal manifestations of NBCCS patients of the Zurich register 
and compare them with those described in 4 epidemiologi-
cal studies performed in other countries.  Methods: We ana-
lyzed patient characteristics and clinical manifestations in a 
register of 30 NBCCS patients in Zurich, Switzerland. We 
compared our findings to the results of 4 epidemiological 
studies performed in America, Australia, Japan and the UK. 
 Results: We obtained information concerning basal cell car-
cinomas (BCCs) and jaw cysts from 28 patients out of our 
population of 30 NBCCS patients. The mean age at onset of 
the first BCC was 24 years, and the mean age at diagnosis of 
the first jaw cyst was 15.6 years. The average number of jaw 
cysts was 8.4; the average number of BCCs was 207. 72.5% of 
the examined BCCs showed a nodular histology, but we also 
found scirrhous and superficial types.  Conclusion: The dis-
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a suppressor of the hedgehog pathway, which leads to the 
activation of smoothened. Smoothened inhibitors (like 
vismodegib) represent new treatment options for ad-
vanced BCC, especially in cases in which the NBCCS 
causes enormous damage and disfigurement in patients 
 [5] .  PTCH1 mutations cannot be identified in every case 
with the clinical findings typical of NBCCS. Wicking et 
al.  [6] showed PTCH protein mutations in 28 of 71 cases, 
86% being truncations of the protein. The same study 
could not indicate a correlation between genotype and 
phenotype. A more recent study by Smith et al.  [7] re-
ported the presence of a missense mutation, an exon copy 
number deletion and nonsense mutation in  SUFU (sup-
pressor of fused), a repressor of the sonic hedgehog  (SHH) 
pathway in NBCCS patients without  PTCH1 mutations.
 Life expectancy with NBCCS is 73.4 years and is sig-
nificantly lower than that of a healthy population in the 
Western world  [8] . However, compared to other heredi-
tary cancer disorders such as neurofibromatosis 1, neuro-
fibromatosis 2, familial adenomatous polyposis and von 
Hippel-Lindau syndrome, NBCCS is associated with the 
smallest reduction in life expectancy. Although only 19% 
of the patient deaths are caused by an attribute of the syn-
drome, NBCCS can negatively impact life quality to a con-
siderable degree  [8] . Therefore, further study is needed to 
increase life quality and life expectancy of NBCCS patients.
 As there is no single symptom or sign supporting di-
agnosis, a positive diagnosis is defined to include either 1 
major criterion plus molecular confirmation, 2 major cri-
teria or 1 major plus 2 minor criteria  [9] . Major criteria 
include: multiple BCCs or early incidence of BCCs (under 
the age of 20), keratocysts of the jaw ( fig. 1 ), palmar/plan-
tar pits, calcification of the falx ( fig.  2 ), rib anomalies, 
ovarian fibromas, medulloblastomas, phalangeal flame-
shaped lucencies and brachymetacarpalism in all 4 limbs. 
Having a first-degree relative with NBCCS is also consid-
ered a major criterion  [10] . Minor criteria include: spina 
bifida occulta or vertebral anomalies, brachymetacarpal-
ism in 1 limb, hypertelorism and frontal bossing.  Table 1 
shows the major and minor criteria for the diagnosis of 
NBCCS. 
 Fig. 1. Orthopantomogram showing odon-
togenic keratocysts (arrows) in one of our 
patients. 
 Fig. 2. Computer tomogram showing calcification of the falx cere-
bri (arrows) in one of our patients. 
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 The following images illustrate the major criteria.
 American, British, Australian and Japanese epidemio-
logical studies investigated the frequency and clinical 
manifestations of NBCCS  [10–13] . The results of these 
studies differ in some aspects, including age of incidence 
of first BCCs and jaw cysts and the frequency of other 
clinical symptoms. So far there has not been any compa-
rable study in Central Europe. In addition to better un-
derstanding NBCCS patient characteristics, we were also 
interested in the typical subtype of BCCs in NBCCS. 
Thus, we undertook an analysis of NBCCS patient char-
acteristics and clinical manifestations in a register of 30 
NBCCS patients in Zurich, Switzerland, and compared 
our results to studies from international populations. We 
note that some of the patients in our study were recruited 
through a self-help group in Germany.
 Methods 
 For further details, see the supplementary materials (for all on-
line suppl. material, see www.karger.com/doi/10.1159/000444792) 
 [9] ( fig. 3 ).
 Results 
 The study population consisted of 13 female and 17 
male patients. The average age was 41.5 years (±18.7 
years), and the median was 38.5 years. 28 patients were 
Caucasian, 2 first-degree related patients were Afro-
American ( table  2 ). There was 1 family consisting of a 
mother and her 2 sons, and another female patient and 
her daughter were included. Of the 30 studied patients, 
we assessed the educational levels of 28. Of these patients, 
11 had a low level of education (1 security man, 1 logisti-
cian, 1 employee of a mountain railway, 1 employee of a 
repair shop, 1 saleswoman, 2 warehouse clerks, 1 elderly 
care nurse, 1 day laborer, 1 chef), 10 an intermediate lev-
el (4 nurses, 1 locomotive driver, 1 musician, 1 IT admin-
istrator, 2 officials, 1 head of logistics), and 3 patients were 
considered as highly educated (1 IT engineer, 1 student, 
1 software engineer). 
 Table 1. Major and minor criteria as suggested by Bree et al. [9]
Major criteria Minor criteria
BCC <20 years or excessive 
numbers of BCCs
Jaw cyst <20 years
Palmar or plantar pitting
Calcification of the falx
cerebri
Medulloblastoma, typically 
desmoplastic
First-degree relative with 
NBCCS
Rib anomalies
Other specific skeletal 
malformations and 
radiological anomalies
Macrocephaly
Cleft lip or palate
Cardiac or ovarian fibroma
Lymphomesenteric cysts
Eye anomalies (strabismus, 
hypertelorism, congenital 
cataract, glaucoma, 
coloboma)
30 patients were screened
(13 females, 17 males)
30 patients were enrolled
1 patient was
excluded due to
lacking consent, but
he consented later on
BCCs of 11 patients
(125 BCCs) were
analyzed
30 patients were
interviewed/examined
Educational levels of
28 patients were
assessed
 Fig. 3. Flowchart of the Methods. 
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 There were 2 patients still attending school and 2 dis-
abled patients. 
 In summary, 46% of the patients had a low level of 
education, 42% an intermediate level and only 12% a high 
level of education.
 In the youngest age class (0–19 years), very few par-
ticipants exhibited BCC, but the second youngest patient 
group (20–39 years) displayed a greater percentage of jaw 
cysts than BCC ( fig. 4 ). The average age at onset of the 
first jaw cyst in this study was 15.6 years which is rather 
young compared to other studies. Dentists and oral sur-
geons should consider the diverse NBCCS, when con-
fronted with a keratocyst of the jaw.
 84% of the patients over 20 years old showed BCC. The 
average age at the first diagnosis of BCC was 24 years ( ta-
ble 2 ).
 In patients with NBCCS, the BCCs occur predomi-
nantly in UV-exposed areas such as the face. But BCC 
 Table 2.  Comparison of clinical manifestations of the NBCCS
Evans et al.
[11] (UK)
Shanley et al. 
[12] (Australia)
Kimonis et al.
[10] (USA)
Endo et al.
[13] (Japan)
This study
(Switzerland)
Patients, n 84 118 105 157 30
Mean age, years n.a. 35 34.5 33.1 41.5
Gender M:F 1:1.3 1:1.3 1:1.2 1.1:1 1:0.76
Patients with BCC 33/70 (47) 90/118 (76) 71/90 (80) 56/148 (37.8) 23/28 (82.11)
Age >20 years 33/45 (73) 71/84 (85) 58/64 (91) 53/103 (51.4) 21/25 (84)
Age >40 years 19/21 (90) 35/37 (95) 34/35 (97) 33/46 (71.7) 11/12 (91.7)
Mean age at first BCC, years n.a. 20.3 21.4 37.4 24
Patients with jaw cysts 46/70 (66) 85/113 (75) 78/105 (74) 126/146 (86.3) 25/28 (89.3)
Age >20 years 37/45 (82) 66/82 (80) 60/74 (81) 92/101 (91.1) 23/26 (88.5)
Age >40 years 19/21 (90) 25/35 (71) 29/38 (76) 32/39 (82) 13/13 (100)
Mean number of jaw cysts per patient n.a. 1 – 28 (6) 1 – 28 (5.1) 1 – 10 (3.68) 0 – 50 (8.4)
Mean age at first jaw cyst, years n.a. 15.5 17.3 19.8 15.6
Patients with pitting 50/70 (71) 82/103 (80) 89/102 (87) 86/143 (60.1) 17/28 (60.7)
Patients with cleft lip/palate 4/70 (5) 4/107 (4) 3/103 (3) 12/133 (9) 3/27 (11.1)
Calcification of falx cerebri n.a. 81/89 (92) 53/82 (65) 78/98 (79.6) 11/13 (84.6)
Patients with medulloblastoma 3/84 (4) 1/118 (1) 4/105 (4) 4/120 (3.3) 0
Patients with ovarian fibroma 6/25 (24) 9/63 (14) 9/52 (17) 5/40 (12.5) 1/12 (8.3)
Figures in parentheses are percentages. n.a. = Not assessed. 
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 Fig. 4. Clinical manifestation in different 
age categories. Jaw cysts = keratocysts of 
the jaw; pits = palmoplantar hyperkerato-
sis. 
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may also occur in non-UV-exposed areas. In the current 
study 80% of the BCCs were located in UV-exposed areas. 
The majority of the histologically examined BCCs were 
nodular (75%;  fig. 5 ). 
 A calcification of the falx cerebri was found or had 
been reported in 84.6% of the cases. Due to the patients’ 
high sensitivity to radiation, no additional radiographs 
were made  [14] . Additional MRI examinations could not 
be realized due to the costs.
 Palmar or plantar pitting was present in 60.7% of the 
patients and a cleft lip or palate in 11.1%.
 Besides the BCC there are additional neoplasias associ-
ated with the NBCCS. Associations are well established 
for medulloblastoma, meningioma and ovarian and car-
diac fibromas. In our patient cohort there was no medul-
loblastoma even though the niece of 1 patient was diag-
nosed with a medulloblastoma at the age of 2 months. 
One of the 12 female patients had an ovarian fibroma. 
Three of the female patients reported myomas, a polycys-
tic ovary and an ovarian cyst, respectively. One male pa-
tient suffered from the very rare cardiac fibroma. No ad-
ditional echocardiographies were performed. Two pa-
tients suffered from meningioma, and there were 5 cases 
of other neoplasias, including non-Hodgkin lymphoma, 
prostate cancer, microadenoma of the pituitary gland, 
carcinoma of the sigmoid colon, a mammary tumor and 
a neurinoma.
 Ophthalmological disorders such as cataract, colobo-
ma and microphthalmos can occur  [11] . In this study 25% 
of the patients had ophthalmological disorders (e.g. cata-
ract, detached retina with cataract, a rubeosis iridis and 
an orbital exenteration and unexplained blindness in 1 
eye). 50% of the patients had a first-degree relative with 
known NBCCS.
 Discussion 
 It has been suggested that there is a need for a genetic 
register which would facilitate disease screening, thus 
leading to earlier diagnosis and follow-up and ultimately 
improved patient survival  [15] . More recently, improved 
survival of patients with hereditary cancers has been 
demonstrated in association with the establishment of 
such a genetic register, emphasizing the need for this type 
of registries  [8] .
 Four major studies investigated the clinical presenta-
tions of NBCCS. These studies were performed on popu-
lations in the UK  [11] , Australia  [12] , the USA  [10] and 
Japan  [13] .
 The aim of our study was to investigate the clinical 
presentations of NBCCS in a patient group in Zurich, 
Switzerland, and to compare our results to international 
data. In addition, we were especially interested in the his-
tological subtypes of BCC associated with the NBCCS. 
Our data show that all BCC subtypes are found in NBCCS 
patients, with nodular and superficial BCCs being the 
most common ones ( fig. 5 ). Nodular BCC is also the most 
common type of BCC in the general population as well as 
in NBCCS patients. Wrone et al.  [16] examined the fre-
quency of different BCC subtypes seen in dermatology 
clinics in a Veterans Affairs health care system in the USA 
and reported that 63.1% of BCC cases were nodular and 
10.7% superficial. An even higher rate of the nodular sub-
type of BCC was reported by Scrivener et al.  [17] . These 
authors analyzed BCC cases diagnosed at a single center 
of dermatopathology from 1967 to 1996 and found that 
78.7% of the cases were nodular, 15.1% superficial and 
6.2% morpheiform. Dreier et al.  [18] analyzed the fre-
quency of complicated BCC cases and found that from 
more than 2,000 BCCs 6.6% were moderate (4–9 BCCs in 
5 years, relapse/complications/hospitalizations during 
investigated years) and 0.6% were severe (extended/met-
astatic disease with >10 BCCs or need for extensive treat-
ment). Patients with moderate or severe BCCs may par-
ticularly benefit from new therapeutic options.
9%
2%
1%
13%
Multilocular/superficial
Solid/nodular
Scirrhous
Metatypical
Desmoplastic
75%
 Fig. 5. BCC subtypes found in the NBCCS patients examined. 
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 Given the considerable variety of the NBCCS symp-
toms, the frequencies of major and minor criteria ob-
served are surprisingly similar compared with interna-
tional results  [10] , but there are some distinct and inter-
esting differences between the various reports. 
 Japanese patients seem to have a reduced frequency 
of BCCs and develop BCCs later in life (37.4 years)  [13] . 
We assume this peculiarity to be due to genetic differ-
ences. Nevertheless, the sun-avoiding habits of the Japa-
nese could play a role as well. In Switzerland, 84% of the 
patients over the age of 20 had 1 or more BCCs. This is 
within the range of other nations even though the Brit-
ish patients over 20 years showed a lower frequency of 
73%  [11] . The mean age incidence of the first BCC in 
Switzerland (24 years) is similar to that in the USA and 
Australia. The high overall incidence of BCCs in the 
USA and Australia could be caused by the tanning hab-
its of the Americans and the intense UV irradiation in 
Australia along with the predominance of fair skin types 
in both countries  [10, 12] . According to our findings, 
80% of the BCCs of NBCCS patients were located in UV-
exposed parts of the body; consequently, doctors and 
pediatricians should brief their NBCCS patients on UV 
protection very early in life. Interestingly, all BCC sub-
types were found which suggests that  SHH signaling is 
relevant for all BCC types. 
 Odontogenic keratocysts are an important major cri-
terion and have been reported in some studies as even 
more prevalent than BCCs. Nevertheless, patients with 
 SUFU mutation show a 20 times higher risk of medul-
loblastoma than patients with  PTCH1 mutations  [7] . 
Compared with international results, Japan has the 
highest prevalence of jaw cysts at 91.1%  [13] . Our study 
showed a high frequency of jaw cysts (89.3%) and the 
lowest mean age at the diagnosis of the first jaw cyst 
(15.6 years). There might be a slight bias in the low age 
at discovery of jaw cysts because some of the patients in 
this study were referred by oral surgeons. However, the 
young age and high prevalence of jaw cysts underline the 
importance of regular and early radiological and dental 
examinations. 
 The frequency of palmar and plantar pitting varied 
from 60.2% in our study group up to 87% in the American 
study; this latter observation no doubt contributes to the 
American authors’ belief in pitting as a useful diagnostic 
criterion  [10] . According to Shanley et al.  [12] , the pitting 
was rather palmar than plantar and was more clearly vis-
ible after a water bath. In one of our NBCCS patients who 
underwent therapy with a smoothened inhibitor, we saw 
a complete disappearance of the palmar pits ( fig. 6 ).
 Cleft lip or palate occurred in the Swiss group in 11.1% 
of cases, which is more frequent than in all other reports. 
Japan was closest to the results of Switzerland with 9% 
 [13] . The remaining studies showed a prevalence of 
3–5%.
 In our study, calcification of the falx cerebri was found 
in 11 of 13 patients with a radiograph (84.6%) which is 
less often than in other studies. This is possibly attribut-
able to the fact that no additional radiographs in the Swiss 
and Japanese study settings have been undertaken. 
a b
 Fig. 6.  a Palmar pits before starting the smoothened inhibitor therapy with LEQ-506 (Novartis) in August 2006. 
 b Complete disappearance of the pits in the same patient in February 2015, 3 months after termination of the 
therapy. 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
D
ow
nl
oa
de
d 
by
: 
Ve
rla
g 
S.
 K
AR
G
ER
 A
G
, B
AS
EL
   
   
   
   
   
   
   
   
   
  
17
2.
16
.6
.9
1 
- 5
/2
/2
01
6 
9:
02
:0
3 
AM
 Gorlin-Goltz Syndrome in Switzerland Dermatology
DOI: 10.1159/000444792
7
 Only 1 female patient was documented with an ovar-
ian fibroma. In the British study, up to every fourth fe-
male patient had an ovarian fibroma  [11] . It is important 
to detect ovarian fibromas even if they are benign in order 
to anticipate the threat of an ovarian torsion and infarc-
tion and to prevent severer consequences  [11] .
 Ophthalmological disorders were rather rare, whereas 
in the British study 26% of the patients had eye problems 
such as strabismus, nystagmus, cataract and microph-
thalmia  [11] . In the American study 19% of patients 
showed a strabismus  [10] .
 50% of the Swiss patients had a first-degree relative 
with a known NBCCS, which is similar to the findings of 
the Japanese study with 48.4%.
 Our study is the first systematic collection of patients 
with NBCCS in continental Europe. It describes the re-
sults from the early stages of the Zurich Register of Gor-
lin-Goltz Patients.
 The number of patients included in this study was lim-
ited. Bias existed due to the inclusion of subjects who had 
been taking part in hedgehog inhibitor trials. 
 Precise declaration of the number of BCCs represents 
another difficulty because three-digit numbers are hard 
to recall for patients. A similar problem arises when col-
lecting data concerning numbers of BCCs in UV-exposed 
versus nonexposed areas. 
 In order to obtain exact numbers of skeletal abnor-
malities like anomalies of the ribs, vertebrae and metacar-
pals, a systematic radiological examination of the skull, 
chest and spine plus the hands and feet would be neces-
sary; however, this is a delicate matter with patients who 
have a tendency to develop BCCs in radiation-exposed 
areas. 
 A further aspect which will be examined is the correla-
tion between genotype and phenotype. We collected sam-
ples of blood and BCC tissue of most of our patients in 
order to examine this correlation in a future study.
 Conclusion 
 The disease burden associated with NBCCS in Swiss 
patients is significant and comparable to other countries. 
 The international consensus statement concerning the 
surveillance guidelines covers the important symptoms 
seen in our patients as well as in other studies  [9] . Al-
though the first BCCs show only later in life (in our study 
the average age is 24), regular skin examinations should 
be considered. UV protection early in life is extremely 
important. 
 In our study as well as in another, some patients had 
their first jaw cyst over the age of 20 years  [19] . Therefore, 
we would suggest undertaking repeated oromaxillary ex-
aminations after the first 2 decades. Due to the sensitivity 
of NBCCS patients to radiation, MRI examinations 
should be discussed.
 There are many unknown or little understood vari-
ables in this syndrome. Little is known about the correla-
tion between genotype and phenotype. While some au-
thors have seen no such correlation, others have observed 
very significant ones  [6, 7] . Therefore, this correlation 
should be examined more thoroughly.
 In 2012, the first oral smoothened inhibitor vismo-
degib was approved for treatment of BCC. Vismodegib 
has been shown to achieve significant tumor regressions 
including complete responses in locally advanced and 
metastatic BCC  [5, 20–22] . The rate of low-grade adverse 
events (e.g. muscle spasms, alopecia, disgeusia, weight 
loss, asthenia) is substantial, but the documented im-
provement or preservation of quality of life for treated 
patients makes vismodegib a novel therapeutic modality 
with a positive benefit-to-risk ratio for patients with ad-
vanced BCC  [23, 24] .
 Vismodegib shrinks some keratocystic odontogenic 
tumors of the jaw in patients with NBCCS and may offer 
an alternative to surgical therapy  [25] . This smoothened 
inhibitor-induced tumor regression is accompanied by a 
dynamic change of the microenvironment with a disrup-
tion of immune privilege involving an influx of cytotoxic 
T cells, activation of the adaptive immune functions, and 
a profound alteration of the local chemokine/cytokine 
network  [26] .
 Familial predisposition to medulloblastoma is well 
known to occur in association with germline mutations 
of  PTCH1 in patients with NBCCS. In some medulloblas-
toma patients, a germline mutation has been discovered 
in  SUFU, a repressor in the  SHH pathway. Thus, inhibit-
ing the  SHH signaling pathway is an ideal candidate ther-
apy for medulloblastoma  [27, 28] .
 This is the first systematic collection of patients with 
NBCCS in Switzerland. The clinical manifestations asso-
ciated with NBCCS in Swiss patients are comparable to 
those of other countries. Recruitment of more patients 
would be beneficial to study this disease. 
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